DexCom, Inc. (DXCM) Stock Score, Valuation & Financial Research
DexCom, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 51/100.
Quick answer for DXCM
DexCom, Inc. currently has a Wall Street Score of 51/100. The stored market price is $83.03. Its financial score is 38/100. Its valuation score is 31/100. The latest WSS change is +0.8 points. These figures are a research snapshot, not a buy or sell recommendation.
What DexCom, Inc. does
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Irela
DXCM financial snapshot
- Wall Street Score:
- 51/100
- Current price:
- $83.03
- Market capitalization:
- $31.33B
- Revenue:
- $4.97B
- Net income:
- $999.7M
- Free cash flow:
- $1.08B
- Cash:
- $1.10B
- Total debt:
- $1.40B
- EPS:
- 2.59
- P/E ratio:
- 32.1x
- Financial score:
- 38/100
- Valuation score:
- 31/100
- Revenue score:
- 30/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $1.08B, showing positive cash generation.
- The balance sheet shows $1.10B of cash versus $1.40B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.8 points: DXCM increased 0.8 points because Valuation improved by 3.2 points.
What the numbers mean
Its current valuation score is 31/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 38/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-06.
How to research DXCM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.